Kornimate/medical-research-clean huggingface dataset:
growth hormone in poor responders to ivf trial

Conditions: Infertility

Summary: this study (the "adjuvant growth hormone study") is being done to see the effects of adding growth hormone (gh) during fertility treatment (also called in vitro fertilization or ivf). growth hormone is a protein that your body normally produces. growth hormone can act on several different organs, including the ovaries, where eggs are made. from evidence gathered from studies done by fertility doctors over the years, researchers believe that women who have not become pregnant through ivf in the past might have better results if they go on a course of growth hormone during the ivf treatment. however, more research needs to be done to confirm whether adding growth hormone is beneficial and also to find out the best time to start growth hormone treatment during ivf. we hope that our adjuvant growth hormone study will help answer these questions.


Eligibility criteria:
inclusion criteria: * subject with prior poor response(s) to ovarian stimulation for ivf or icsi. poor response is defined as a history of producing fewer than four follicles ≥14 mm in diameter during previous cos cycles where fsh or hmg was used from cycle start at a daily dose of ≥450 iu * age ≤ 45 years * baseline blood labs, measured within previous month, show fasting blood glucose \<6.1 mmol/l and tsh ≤ 5.5 mu/l * early follicular phase (day 2 or day 3) serum fsh, evaluated in the preceding 6 months * subject willing and able to give informed consent exclusion criteria: * concurrently enrolled in any other clinical trial * previous participation in this study * using gnrh agonist in cos protocol * any prior early follicular phase serum fsh level ≥12 iu/l * use of any of the following is contraindicated or inappropriate: gh, cetrotide®, fsh, lh or hcg * used ocp within the prior month * pregnant or lactating * untreated hydrosalpinx * tobacco smoker * diabetic or otherwise at risk of gestational diabetes * bmi \> 38 kg/m2 * poorly controlled thyroid disease * known cancer or prior history of malignancies

Keywords: infertility poor responder in vitro fertilization growth hormone
vestibular function in cochlear implants

Conditions: Cochlear Trauma; Vestibular Disorder; Deafness, Bilateral

Summary: the objective of this study is to identify possible preoperative risk factors including genetic background and to suggest the optimal test battery of vestibular function in cochlear implant recipients

the objective of this study is to identify possible preoperative risk factors including genetic background and to suggest the optimal test battery of vestibular function in cochlear implant recipients participants underwent standard vestibular testing including video head impulse test (vhit), vestibular evoked myogenic potentials (vemp), subjective visual vertical and stabilometry before and after the surgery.

Eligibility criteria:
inclusion criteria: * profound bilateral sensorineural hearing loss meeting criteria for cochlear implantation exclusion criteria: * profound unilateral sensorineural hearing loss meeting criteria for cochlear implantation

Keywords: cochlear implant
the effect of supplementation of vitamin d3 on inflammation induced by 100 km running, iron metabolism and erythropoiesis

Conditions: Inflammation; Muscle; Iron Metabolism; Ineffective Erythropoiesis; Healthy

Summary: a group of runners received vitamin d (10,000 iu - international unit per day) for two weeks. the aim of the intervention was to check the effect of vitamin d supplementation on selected parameters of inflammation and iron metabolism in comparison with the placebo group. blood was collected before and after supplementation. next: before, after 25, 50, 75,100 km running and 12 hours after the run. the data were subjected to statistical analysis.

subjects were randomized to two groups: the experimental one, n = 20 and the placebo one, n = 20 with the same age, experience in running and 25(oh)d level. the experimental group received vitamin d3 supplementation (around 10,000 ui/day, i.e., 20 droplets -vigantol medicament, merck) and the control group received a placebo (20 droplets of sunflower oil, placed in an identical bottle as vitamin d3) for two weeks before a run. the last vitamin d dose was taken 24 h before the 100 km ultra-marathon. 40 male athletes took part in the 100 km ultra-marathon. blood was collected before (day 0) and after supplementation (day 14). next (day 15): before, after 25, 50, 75,100 km running and 12 hours after the run (day 16). the data were subjected to statistical analysis.

Eligibility criteria:
inclusion criteria: * male * athletes running ultra-marathons exclusion criteria: * vitamin d3 supplementation * multivitamin and iron supplementation * serum 25(oh)d low \< 10 ng/ml * serum 25(oh)d high \> 100 ng/ml * haemoglobin \< 10 g/dl * other (sports injury, tournament)

Keywords: vitamin d running inflammations erythropoietin iron hepcidin
a study to evaluate the efficacy and safety of co-administration of ad-227a and ad-227b

Conditions: Essential Hypertension

Summary: the purpose of this study is to evaluate the efficacy and safety of co-administration of ad-227a and ad-227b in patients with essential hypertension

essential hypertension

Eligibility criteria:
inclusion criteria: * signed informed consent * patients with essential hypertension * other inclusions applied exclusion criteria: * patient with secondary hypertension * other exclusions applied
occlusion vs standard treatment for the treatment of herpes zoster

Conditions: Herpes Zoster

Summary: this study evaluates the addition of occlusive dressings (hydrocolloids) or topical silicone gel in the treatment of shingles (herpes zoster). one third of the participants will receive a hydrocolloid occlusive dressing, one third will receive the topical silicone gel and one third will receive the current treatment of the rash consisting of drying solutions (soaks).

herpes zoster (hz), also known shingles, is a viral disease caused by the varicella-zoster virus. it is considered a local reactivation of varicella (chicken pox). the rash of herpes zoster is characterized by vesicles that appear following a single dermatome (the territory that is innervated by one spinal nerve). these vesicles may be very painful and cause discomfort due to draining and crusting. when a person becomes sick with shingles healthcare professionals prescribe systemic (oral) treatment with antivirals (e.g. acyclovir) and pain medication according to the type and severity. to treat the local lesions caused by shingles, over the centuries, patients have been treated with drying solutions and drying powders. this practice has been passed on through the years without any evidence supporting its effectiveness, in all likelihood due to the fact that the rash is self-limited to 2 to 3 weeks. recently, new evidence has shown that the vesicles that appear with the shingles rash are not superficial but involve deeper areas of the skin and should be considered partial thickness wounds. since 1962, it has become clear that partial thickness wounds benefit from occlusive therapy (keeping wounds closed and avoiding drying) such as dressings and occlusive gels that keep the wound wet rather than allowing it to dry. in this clinical trial the investigators believe that given this information, using occlusive therapy with a hydrocolloid dressing or a silicone-based gel may heal the rash of herpes zoster, decrease pain and improve the quality of life, much faster than the treatment currently used of drying the area with powders and solutions.

Eligibility criteria:
inclusion criteria: * patients with clinical diagnosis of hz confirmed by a certified dermatologist * patients having maximum 72 hours from the start of the first vesicle * older than 18 years exclusion criteria: * patients with dimethicone allergy * patients with hydrocolloid allergy * patients with acetaminophen allergy * patients with aluminium sulphate and calcium acetate allergy * patients with acyclovir allergy * pregnant women * breastfeeding women * unable to give informed consent * patients with signs of infection over the skin rash * patients with disseminated hz * patients with hemorrhagic hz * patients with complications such as pneumonia or encephalitis * patients unable to apply the treatment to the affected area * patients with hz-associated keratitis * patients whose rash is located to hairy areas that may hinder occlusion with the hydrocolloid dressing.
bariatric surgery and pharmacokinetics of fluoxetine

Conditions: Obesity, Morbid

Summary: changes to gastric ph, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. these factors are potentially influenced by bariatric surgery. little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. in this study the pharmacokinetic effects of bariatric surgery on fluoxetine are investigated.


Eligibility criteria:
inclusion criteria: * preparing to undergo gastric bypass or sleeve gastrectomy in central norway * being a norwegian citizen exclusion criteria: * having previously undergone resections in the gi-tract

Keywords: bariatric surgery gastrointestinal tract biological availability pharmacokinetics fluoxetine
protectiscope cs intended for diagnostic and therapeutic colonoscopy

Conditions: Colon Cancer

Summary: the purpose of this study is to determine whether the protectiscope cs is capable to perform diagnostic and therapeutic colonoscopy.

the protectiscope cs is a disposable-based colonoscope incorporating a miniature video camera,integral light source along with single-use sleeves and application channels. the protectiscope cs is intended to provide visualization and therapeutic access to the lower gastrointestinal tract, in adult patient populations.

Eligibility criteria:
inclusion criteria: * subject between the ages of 18 and 80 * subject is indicated for screening colonoscopy * subject is willing to sign informed consent form exclusion criteria: * subject is suspected, based on radiographic or other clinical grounds, of suffering from one or more of the following: full or partial colonic obstruction; acute abdomen; gross hematochezia; severely ulcerated colon; diverticulitis; severe diverticulosis; toxic megacolon. * subject has active cardiac problems and history of heart failure, severe pulmonary diseases renal failure (creatinine \>2) uncontrolled diabetes and any other illness judged by investigator to substantiate exclusion. * subject has a history of significant other diseases. * subject has a history of psychiatric disorders which would prevent compliance with study instructions * for female subjects, suspicion of pregnancy * subject has received treatment with another investigational drug or device within the past 30 days

Keywords: colonoscopy disposable single use
pilot testing a novel remotely delivered intensive outpatient program for individuals with oud

Conditions: Opioid Use Disorder; Serious Bacterial Infections

Summary: this study aims to test a remotely delivered iop program ("smartiop") for oud patients who are hospitalized for serious injection-related infections. this will be a pilot trial to assess the feasibility of the iop program and examine oud-related outcomes following discharge from the hospital.

the aim is to conduct a single-arm pilot study of 20 participants who are hospitalized for serious injection-related infections to complete the newly tailored program. the intervention to be developed and tested has two components: 1) the remotely delivered iop ("smart iop"), and 2) a peer recovery coach who will provide support and accountability to the participant. the feasibility of the intervention will be established by evaluating recruitment and the acceptability of the program according to a priori benchmarks. the study team will assess the program's preliminary efficacy by evaluating oud-related outcomes for up to 28 days after discharge from the hospital. the study will be conducted at brigham and women's hospital (bwh), an urban, 793-bed academic medical center located in boston, ma, and a major teaching hospital for harvard medical school.

Eligibility criteria:
inclusion criteria: * english-speaking adults aged 18 and above * any dsm-5 substance use disorder * can identify at least 2 individuals who can act as points of contact following discharge from the hospital exclusion criteria: * psychotic disorder, active suicidality, or homicidally * condition likely to be terminal during the study period * unable to perform consent due to impaired mental status
factors affecting the incidence of postoperative delirium in frail elderly

Conditions: Postoperative Delirium

Summary: postoperative delirium has been found to be associated with increased risk of future neurocognitive decline and mortality especially in elderly patients. similarly, frailty has been found to be associated with an increased risk of postoperative complication including delirium in the elderly.the purpose of this study is determine the factors affecting the incidence of postoperative delirium in frail elderly undergoing non-cardiac surgery in the singapore population.


Eligibility criteria:
inclusion criteria: * elderly (\> 65 years) frail patients undergoing non cardiac surgery under anaesthesia lasting for \>60 minutes * patient willing and able to complete the requirements of this study. exclusion criteria: * disabling neuropsychiatric or neurological disorders(including severe dementia, alzheimer's disease, schizophrenia, severe depression) * patients suffering from delirium at selection; * patients who cannot complete the preoperative mental tests (cam and/or mini-mental state examination (mmse)) of this clinical trial;

Keywords: postoperative delirium
implantation rate of vitrified-warmed collapsed blastocysts

Conditions: Implantation Rate of Vitrified Blastocysts

Summary: in our centre, the implantation rate of frozen blastocysts (cryopreserved using vitrification)was 20,3% (van landuyt et al. 2011). this implantation rate is lower when compared to data from other observational studies. retrospective studies have shown that artificial shrinkage of the blastocoelic cavity (also called collapse) and dehydration of the blastocyst just before vitrification can have a positive effect on the survival after warming. this collapse can be induced by using a laser. the study of iwayama et al. 2010 has shown a similar survival rate but an increase in the implantation rate of collapsed blastocysts compared to non-collapsed blastocysts. the aim of the study is to investigate the effect of artificial shrinkage by laser-induced collapse on the implantation potential of vitrified-warmed day 5 or day 6 blastocyst stage embryos in a prospective randomised controlled trial.


Eligibility criteria:
inclusion criteria: * female age \<39 years * at least 1 blastocyst available for cryopreservation exclusion criteria: * sperm origin: testicular or epididymal sperm extraction * ivm (in-vitro maturation) cycles * pgd cycles (preimplantation genetic diagnosis)

Keywords: vitrification, blastocyst, artificial shrinkage, collapse
influences of balance training with a dynamometric platform in total knee arthroplasty

Conditions: Knee Osteoarthritis

Summary: knee osteoarthritis produces degeneration and joint wear that greatly affects the patient's proprioceptive system increasing instability. after total knee arthroplasty intervention, it is recommended that the patient performs a rehabilitation procedure to minimize deficits caused by surgery. in this job it is essential to insist on the importance of recovering balance after total knee arthroplasty intervention, and assess a specifically designed protocol to restore its function. an intervention which includes a dynamometric platform as a training method was proposed. the randomized clinical trial compared a control group that performed balance exercises on parallel bars, unstable plates, ramps and stairs against an experimental group that included dynamometric platforms training as a differentiator.


Eligibility criteria:
inclusion criteria: * age between 65 and 85. * subjects with knee osteoarthritis that have not been operated before. * patients operated with the same total replacement prosthesis. * patients operated with the same surgical procedure. * time before intervention over 4 weeks. * time to start rehabilitation after surgery must be less than 4 weeks. * the result in berg scale must be greater than 21, indicating a medium-low risk of falling. * the result of the mini-mental state examination must be equal or greater than 20, which means they do not have moderate or severe cognitive impairment. * once the informed consent is read and explained, patients must accept and agree to participate in the study. exclusion criteria: * patient does no accept sign the informed consent. * patient with morphological alterations hip or ankle (also knee). * patient that presents knee flexion out of the range between 70 ° and -20 ° because of the risk posed to suffer a fall. * patient with suspected deep vein thrombosis. * patient with post-surgical infection of the operated knee. * patient with psychiatric disorders: depression, anxious syndrome, etc. * patient with pathology of central origin (i.e. cerebellar) that could interfere with the results of the test of balance or strength * patient with vestibular pathology that could interfere with the results of the test of balance

Keywords: total knee replacement total knee arthroplasty rehabilitation physical therapy balance
incidence of allergic manifestations and infectious episodes in healthy term infants at risk for dysbiosis

Conditions: Dermatitis, Allergic Contact; Infectious Diseases

Summary: this study will evaluate the incidence of allergic manifestations (the first of which is atopic dermatitis) and infectious diseases in children fed with an infant formula under real conditions of use.

the primary objective of the study is to evaluate the cumulative incidence of atopic dermatitis in healthy infants at risk for dysbiosis at 12 months of age and to identify factors associated with the presence of atopic dermatitis.

Eligibility criteria:
inclusion criteria: * full-term infant (gestational age ≥ 37 and ≤ 42 weeks) in good health; * having at least one risk factor for dysbiosis, including: * birth by caesarean section, * antibiotic exposure between birth and inclusion or in utero (mother who received antibiotics) during the last trimester of pregnancy, or per-partum (mother who received antibiotics during childbirth), * a family history of allergy confirmed by a doctor in a family member, affecting at least one of the two parents or siblings (asthma, atopic dermatitis, eczema, allergic rhinitis, proven food allergy); * aged at most 5 weeks; * having a weight in the reference values for gestational age and sex (between the 10th and the 90th percentiles according to the growth curves in force); * already consuming an infant formula (with or without associated breast milk), or whose mother wishes to introduce an infant formula at the end of this consultation to switch to mixed breastfeeding or to start weaning; * authorization of a parent (or both) or legal representative of the child to collect personal information about their child and family. exclusion criteria: * premature infants or low birth weight (\< 2500g); * infant allergic to cow's milk protein; * infants with severe congenital anomalies that may impact growth (cystic fibrosis, bronchopulmonary dysplasia, tracheomalacia, tracheoesophageal fistula, congenital heart defects ...); * infants with chronic disease or severe neonatal pathology, or a pathology predisposing to infections (hiv, hepatitis b or c, autoimmune diabetes, immune deficiency, respiratory distress, sepsis, intraventricular hemorrhage, severe neonatal hepatitis, necrotizing enterocolitis, hypertension persistent pulmonary ...), or renal or hepatic pathology; * inability of the parent or legal representative to understand the protocol of the study, or doubts of the physician on the ability or willingness to comply with the protocol.
efficacy and safety of intravenous immunoglobulin igpro10 in patients with primary immunodeficiencies (pid)

Conditions: Agammaglobulinemia; IgG Deficiency; Common Variable Immunodeficiency

Summary: the purpose of this study is to demonstrate the effect of igpro10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. as secondary endpoints the rate of overall infections, the tolerability and safety of igpro10 are studied. a part of the patients are participating in a pharmacokinetic substudy.


Eligibility criteria:
key inclusion criteria: * patients with primary immunodeficiency * patients who have received stable ivig therapy at 3- or 4-weekly intervals for at least 6 months key exclusion criteria: * newly diagnosed pid * allergic reactions to immunoglobulins or other blood products * administration of steroids (daily ≥ 0.15 mg prednisone equivalent/kg/day) or other immunosuppressive drugs * concomitant diseases such as hypoalbuminemia, protein-losing enteropathies, kidney diseases with proteinuria, malignancies of lymphoid cells (e.g. lymphocytic leukemia), and recent history of migraine * history of cardiac insufficiency (nyha iii/iv), cardiomyopathy, congestive heart failure, severe hypertension

Keywords: immunoglobulin intravenous agammaglobulinemia hypogammaglobulinemia common variable immunodeficiency immunoglobulin g children
baseline investigation of patients with cardiac arrest in china

Conditions: Cardiac Arrest

Summary: basic is a perspective, multicentre and large-scale registry focusing on of patients suffering a cardiac arrest in china. the aims of the study are to establish the monitoring sites covering out-of-hospital cardiac arrest (ohca) and in-hospital cardiac arrest (ihca) in urban and rural areas in 7 regions (east china, north china, south china, central china, northeast china, southwest china and northwest china) around china, to collect data from cardiac arrest patients, and to describe basic characteristics, treatments, outcomes, incidences and risk factors of ohca and ihca in china.


Eligibility criteria:
inclusion criteria: 1. ohca: every patient who suffered a cardiac arrest that occurred in any location other than a hospital, and was attended and/or treated by an ems. 2. ihca: every patient who suffered a cardiac arrest in hospital. 3. the representative population-based survey: every patient who suffered a cardiac arrest in the selected cities or suburbs. exclusion criteria: 1. ohca: 1)the out-of-hospital cardiac arrest patients who were taken to the hospital by their family members; 2) bystanders suspected cardiac arrest, but the rosc was achieved without defibrillation or resuscitation by ems. 2. ihca: the patient who suffered a cardiac arrest that occurred out-of-hospital and then transferred to the hospital.